These results match the mutational profile that was already described in literature with RNF43 mutations marking low-grade lesions while invasiveness-associated mutations CDKN2A and SMAD4 were found in HGD IPMN and PDAC13. This evidence concerns the gene CDKN2A and pancreatic intraductal papillary-mucinous neoplasm.